Cargando…
Using amyloid PET imaging to diagnose Alzheimer’s disease in patients with multiple sclerosis
BACKGROUND: Cognitive dysfunction affects 40–60% of individuals with multiple sclerosis (MS). The neuropsychological profile commonly consists of a subcortical pattern of deficits, although a proportion of patients have a severe progressive cortical dementia. However, patients with MS can be affecte...
Autores principales: | Kolanko, Magdalena, Win, Zarni, Patel, Neva, Malik, Omar, Carswell, Christopher, Gontsarova, Anastassia, Nicholas, Richard, Perry, Richard, Malhotra, Paresh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578168/ https://www.ncbi.nlm.nih.gov/pubmed/32556533 http://dx.doi.org/10.1007/s00415-020-09969-z |
Ejemplares similares
-
Visual atrophy rating scales and amyloid PET status in an Alzheimer's disease clinical cohort
por: Loreto, Flavia, et al.
Publicado: (2023) -
Evaluating cognitive profiles of patients undergoing clinical amyloid-PET imaging
por: Loreto, Flavia, et al.
Publicado: (2021) -
A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease
por: Inglese, Marianna, et al.
Publicado: (2022) -
Diagnosed Mild Cognitive Impairment Due to Alzheimer’s Disease with PET Biomarkers of Beta Amyloid and Neuronal Dysfunction
por: Hatashita, Shizuo, et al.
Publicado: (2013) -
FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)